Agenus | AGEN - Equity Capital And Reserves


Agenus reported $-221.22M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Agenus USD -221.22M 49.89M Mar/2026
Amgen USD 9.19B 532M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Celldex Therapeutics USD 456.23M 70.94M Mar/2026
CSL USD 18.66B 2.75B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
J&J USD 81.19B 358M Mar/2026
Jiangsu Hengrui CNY 63.63B 2.35B Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
MacroGenics USD 21.2M 34.39M Mar/2026
Merck EUR 29.74B 1.15B Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -144.76M 17.01M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Veracyte USD 1.34B 34.83M Mar/2026